PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT No. 19-3640 IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORINE AND NALOXONE) ANTITRUST LITIGATION INDIVIOR INC. F/K/A RECKITT BENCKISER PHARMACEUTICALS, INC., APPELLANT (E.D. Pa. No. 02-13-md-02445) Argued on July 1, 2020 (Opinion filed: July 28, 2020) Before: GREENAWAY JR, SHWARTZ, and RENDELL, Circuit Judges Bruce E. Gerstein Joseph Opper Garwin Gerstein & Fisher Wall Street Plaza 88 Pine Street, 10th Floor New York, NY 10036 Counsel for Plaintiff-Appellee Burlington Drug Co. Inc. Thomas M. Sobol Hagens Berman Sobol Shapiro 55 Cambridge Parkway Suite 301 Cambridge, MA 02142  Counsel for Plaintiff-Appellees Meijer Inc. and Meijer Distribution Inc. Caitlin G. Coslett David F. Sorensen Berger Montague 1818 Market Street Suite 3600 Philadelphia, PA 19103 Peter Kohn [ARGUED] Faruqi & Faruqi 1617 John F. Kennedy Boulevard Suite 1550 Philadelphia, PA 19103 Counsel for Plaintiff-Appellee Rochester Drug Cooperative Inc. Jonathan B. Berman [ARGUED] Jones Day 51 Louisiana Avenue, N.W. Washington, DC 20001 James R. Saywell Jones Day 901 Lakeside Avenue North Point Cleveland, OH 44114 Counsel for Defendant-Appellant Indivior Inc., f/k/a Reckitt Benckiser Pharmaceuticals Inc. Anthony Russomanno Wisconsin Department of Justice P.O. Box 7857 Madison, WI 53707 Counsel for Amicus State of Wisconsin in support of Appellees Randy Stutz 10418 Ewell Avenue Kensington, MD 20895 Counsel for Amicus American Antitrust Institute in support of Appellees SHWARTZ, Circuit Judge: ORDER AMENDING OPINION IT IS ORDERED, that the published Opinion in the above case, filed on July 28, 2020, be amended as follows: On page 11, footnote 9: Reckitt argues that the lawfulness of pricing conduct renders class certification improper. Regardless, in this case, the allegedly unlawful nonpricing conduct could be established via common evidence and thus satisfy the commonality requirement. The amendment does not change the date of filing, July 28, 2020. By the Court, s/Patty Shwartz Circuit Judge